新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 癌症研究 » Cancer:药物埃罗替尼或可有效延长宫颈癌患者的寿命

Cancer:药物埃罗替尼或可有效延长宫颈癌患者的寿命

来源:生物谷 2014-03-10 23:03

埃罗替尼的分子式(来自维基百科)

2014年3月10日 讯 /生物谷BIOON/ --近日,刊登在国际杂志Cancer上的一篇研究论文中,来自巴西国家癌症研究所的研究人员通过进行临床研究表明,一种靶向抗肿瘤药物埃罗替尼或可有效治疗宫颈癌,研究者认为还需要进行大量的试验来证明是否该药物可以作为标准疗法来治疗宫颈癌患者。

每年在全世界范围内有大约50万女性患宫颈癌,这也使得该病成为引发女性死亡的第三大杀手,尽管有很多疫苗针对乳头状瘤病毒的感染,但是宫颈癌仍然是人类,尤其是引发女性健康危机的重要因素。

基于顺铂的放疗法是针对局部恶性宫颈癌的标准疗法,但是很不幸的是该疗法的预期效果并不理想;由于表皮生长因子受体(EGFR)在宫颈癌个体中的表达水平较高,因此以EGFR为靶点的新型疗法或许成为应对宫颈癌的新疗法,在癌症治疗中抑制该受体可以对一系列癌症均有抵御的作用。

文章中研究者Angélica Nogueira-Rodrigues表示,我们对36位宫颈癌患者进行临床II期试验,来检测埃罗替尼和放疗方法的结合疗法对个体病情的作用,其中对患者的平均治疗时间为77天,平均随访时间为59.3个月。结果显示,有34位病人(94.4%)对疗法完全响应,也就是说患者机体中的癌症组织完全并清除了,两年后又91.7%的患者仍存活,而且其中80.6%的患者机体的肿瘤并没有恶化;三年后有80%的患者存活,其中73.8%的患者机体的肿瘤没有恶化。

最后研究者表示,由于宫颈癌是一种很容易被忽略的疾病,因此广大女性需要时刻警惕;这项研究对于科学家们后期开发有效抑制宫颈癌的靶向药物提供了很好的研究思路和研究基础。(生物谷Bioon.com)

doi:10.1002/cncr.28471
Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer

Angelica Nogueira-Rodrigues MD, PhD1,*, Giulliana Moralez MD, MSc1, Rachele Grazziotin MD2, Claudio C. Carmo MD, PhD3, Isabele A. Small MSc1, Flavia V.G. Alves MSc1, Marcelo Mamede MD, PhD1, Felipe Erlich MD, MSc2, Celia Viegas MD, PhD2, Sergio A. Triginelli MD, PhD4, Carlos G. Ferreira MD, PhD1

BACKGROUND Cisplatin-based chemoradiation (CRT) is the standard treatment for patients with locally advanced cervical cancer. Epidermal growth factor receptor (EGFR) is frequently overexpressed in cervical cancer, and EGFR inhibition itself has antitumor effects and potentiates CRT. Results of a previous phase 1 trial of the EGFR inhibitor erlotinib combined with cisplatin-based CRT (E + CRT) recommended a phase 2 erlotinib dose of 150 mg/day. METHODS Eligibility criteria included International Federation of Gynecology and Obstetrics stage IIB to IIIB epidermoid cervical cancer, no prior therapy, and an Eastern Cooperative Oncology Group performance status of 0 to 2. Patients received erlotinib at a dose of 150 mg/day 1 week before and in combination with cisplatin (40 mg/m2 administered weekly for 5 cycles) and radiotherapy (4500 centigrays in 25 fractions), followed by brachytherapy (4 fractions at a dose of 600 centigrays weekly). RESULTS A total of 36 patients completed treatment with E + CRT. The median duration of therapy was 77 days and the median follow-up period was 59.3 months. The therapy was well tolerated overall, and 34 patients (94.4%) achieved a complete response. The 2-year and 3-year cumulative overall and progression-free survival rates were 91.7% and 80.6% and 80% and 73.8%, respectively. CONCLUSIONS Treatment with E + CRT appears to be safe and exerts significant activity against locally advanced cervical cancer. To the best of the authors' knowledge, this is the first study to date to demonstrate that a target agent has promising activity against locally advanced cervical cancer.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库